Septerna (NASDAQ:SEPN) Stock Rating Upgraded by Guggenheim

Septerna (NASDAQ:SEPN) was upgraded by analysts at Guggenheim to a “strong-buy” rating in a research report issued on Thursday,Zacks.com reports.

A number of other brokerages have also recently commented on SEPN. Truist Financial increased their target price on Septerna from $34.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Raymond James Financial increased their price target on Septerna from $47.00 to $53.00 and gave the company a “strong-buy” rating in a report on Monday. Wells Fargo & Company increased their price target on Septerna from $28.00 to $48.00 and gave the company an “overweight” rating in a report on Tuesday, March 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $60.00 price target on shares of Septerna in a report on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $45.78.

Septerna Price Performance

Shares of Septerna stock opened at $34.03 on Thursday. The business has a 50 day simple moving average of $26.75 and a two-hundred day simple moving average of $26.73. Septerna has a 12 month low of $9.85 and a 12 month high of $34.19. The stock has a market capitalization of $1.53 billion, a P/E ratio of -42.01 and a beta of 2.39.

Septerna (NASDAQ:SEPN) last announced its earnings results on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million during the quarter, compared to analysts’ expectations of $16.98 million. As a group, research analysts anticipate that Septerna will post -1.57 EPS for the current fiscal year.

Insider Activity at Septerna

In related news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $4,240,247.06. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samira Shaikhly sold 5,935 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $28.93, for a total value of $171,699.55. Following the completion of the transaction, the insider owned 793 shares of the company’s stock, valued at $22,941.49. The trade was a 88.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 21,733 shares of company stock valued at $623,707. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC grew its position in Septerna by 8.1% in the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after acquiring an additional 100,000 shares during the period. Group One Trading LLC grew its position in Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after acquiring an additional 8,955 shares during the period. Renaissance Technologies LLC purchased a new position in Septerna in the first quarter worth approximately $906,000. Bank of New York Mellon Corp grew its position in Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after acquiring an additional 3,377 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Septerna in the first quarter worth approximately $21,334,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.